Louisiana State University and Agricultural & Mechanical College

Agritech Technologies Ltd.

Other

R. Martin Emanuele

Konstantin G. Kousoulas

Hameedsulthan S. Allaudeen

Konstantin G Kousoulas

William C Fioretti

Vladimir N Chouljenko

Daniel G Satterlee

R Martin Emanuele

Hameedsulthan S Allaudeen

Abolgasem Baghian

Thomas N Tully, Jr

Mark Joseph Newman

James Michael Mathis

The present invention provides compositions for treating or preventing cancer and methods of using and making the compositions. The compositions comprise herpes simplex viruses comprising recombinant herpes simplex virus genomes. Further provided are recombinant herpes simplex virus genomes, viruses comprising the recombinant herpes simplex virus genomes, and cancer vaccines and other compositions comprising the viruses.

Compositions comprising herpes simplex virus-i for use in methods of treating and preventing cancer

The present invention provides vaccines for treating or preventing a herpes simplex virus infection and methods of using and making the vaccine. Further provided are recombinant herpes simplex virus genomes, recombinant viruses, and immunogenic compositions.

Vaccines against genital herpes simplex infections

Embodiments of nucleic acids comprise a nucleotide sequence encoding a live-attenuated chimeric Herpes Simplex Virus Type-1 (HSV-1) VC2 virus and a nucleotide sequence encoding a heterologous polypeptide operably linked to a promoter. The nucleotide sequence encoding the heterologous polypeptide can be operably linked to a promoter encoding the glycoprotein D (gD) of Equine Herpesvirus-1 (EHV-1) or a fragment thereof. Also provided is a live-attenuated recombinant Herpes Simplex Virus Type-1 (HSV-1) VC2 virus comprising a nucleotide sequence encoding a nucleotide sequence encoding a heterologous polypeptide operably linked to a promoter.

Herpes simplex virus type-1(HSV-1) vaccine strain VC2 generating an anti-EHV-1 immune response

A recombinant herpes simplex virus type-1 (HSV-1) has been constructed that carries a deletion of one of the two viral &#x3b3;34.5 genes and other immediate early genes, which render the virus able to selectively replicate in cancer cells but not efficiently replicate in normal cells, and in which specific mutations have been introduced to enable the virus to spread among cancer cells by virus-induced fusion. Specifically, syncytial mutations have been introduced in the genes coding for glycoprotein B and glycoprotein K of the virus, enabling high replication and spread of the virus in cancer cells in the presence of substantially lower amounts of &#x3b3;34.5 protein, which is required for optimum infectious virus produced and virus-induced cell fusion. These altered viruses or the isolated bacterial chromosomes could be used to treat various cancers including breast, liver, colon, and other tissues.

Synthetic herpes simplex viruses type-1 for treatment of cancers

Vaccine compositions protective againstinfections in animals, including but not limited to humans and avian species, comprising an immunogenic amount of amajor outer membrane protein (MOMP) polypeptide lacking regions VD1 and VD2 are provided. Nucleic acid vectors for the expression of MOMP polypeptides and MOMP polypeptide fusion proteins are disclosed. Nucleic acid vectors encoding amajor outer membrane protein (MOMP) polypeptide lacking regions VD1 and VD2 useful for genetic, or 'naked nucleic acid' vaccination are disclosed. Methods for preventing ainfection in a subject using MOMP polypeptides, MOMP polypeptide-fusion proteins, or nucleic acid expression vectors are also provided.

[object Object]

The present invention relates to compositions and methods for delivery of antisense oligonucleotides or other nucleic acid sequences. The present invention comprises a delivery composition comprising an administerable admixture of an effective amount of a nucleic acid sequence and an effective amount of a surface active nonionic block copolymer having the following general formula:HO(CHO)(CHO)(CHO)Hwherein a is an integer such that the hydrophobe represented by (CHO) has a molecular weight between approximately 750 and approximately 15,000, preferably between approximately 2250 and approximately 15,000, more preferably between approximately 3250 and approximately 15,000, and b is an integer such that the hydrophile portion represented by (C2H4O) constitutes approximately 1% to approximately 50% by weight of the compound, preferably approximately 5% to approximately 25%.

Therapeutic delivery compositions and methods of use thereof

The present invention relates to compositions and methods for treating infectious diseases and genetic disorders through gene therapy and intracellular delivery of antisense oligonucleotides or other nucleic acid sequences. In particular, compositions and methods using biologically active nononic reverse block copolymers are described. The reverse copolymers have an inner core of polyoxyethylene (POE) that is flanked on either end by polyoxpropylene (POP). The reverse block copolymers have the following formula:wherein 'b' represents a number such that the molecular weight of the hydrophobe (CHO)is between approximately 750 and 20,000 Daltons and 'a' represents a number such that the percentage of hydrophile (CHO)is between approximately 1% and 90% of the weight of the block copolymer.

Vaccine compositions protective against infections in animals, including but not limited to humans and avian species, comprising an immunogenic amount of a major outer membrane protein (MOMP) polypeptide lacking regions VD1 and VD2 are provided. Nucleic acid vectors for the expression of MOMP polypeptides and MOMP polypeptide fusion proteins are disclosed. Nucleic acid vectors encoding a major outer membrane protein (MOMP) polypeptide lacking regions VD1 and VD2 useful for genetic, or &ldquo;naked nucleic acid&rdquo; vaccination are disclosed. Methods for preventing a infection in a subject using MOMP polypeptides, MOMP polypeptide-fusion proteins, or nucleic acid expression vectors are also provided.

Vaccines for Chlamydia psittaci infections

The present invention relates, in general, to a method of enhancing the production performance of avians, by administering to a bird a heterologous protein comprised of inhibin protein, or a fragment thereof, and a carrier protein. The present invention also relates to a method of enhancing the production performance of avians, by administering to a bird a fusion gene product comprising a gene encoded for the expression of alpha-subunit avian inhibin protein, or a fragment thereof, and a gene encoded for the expression of a carrier protein. An effective amount of the heterologous protein or fusion gene product is administered to an animal such that an immunological response occurs in the animal against the heterologous protein. The present invention further relates to the above heterologous protein and fusion gene product, and to methods of producing the same.

Growing community of inventors

Baton Rouge, LA, United States of America

Konstantin G Kousoulas